TY - JOUR T1 - Estimating pre-symptomatic transmission of COVID-19: a secondary analysis using published data JF - medRxiv DO - 10.1101/2020.05.08.20094870 SP - 2020.05.08.20094870 AU - Miriam Casey AU - John Griffin AU - Conor G. McAloon AU - Andrew W. Byrne AU - Jamie M Madden AU - David Mc Evoy AU - Áine B. Collins AU - Kevin Hunt AU - Ann Barber AU - Francis Butler AU - Elizabeth A. Lane AU - Kirsty O’Brien AU - Patrick Wall AU - Kieran A. Walsh AU - Simon J. More Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/11/2020.05.08.20094870.abstract N2 - Background Understanding the extent of virus transmission that can occur before symptom onset is vital for targeting control measures against the global pandemic of COVID-19.Objective Estimation of (1) the proportion of pre-symptomatic transmission of COVID-19 that can occur and (2) timing of transmission relative to symptom onset.Design Secondary analysis of published dataData sources Meta-analysis of COVID-19 incubation period and a rapid systematic review of serial interval and generation time, which are published separately.Methods Simulations were generated of incubation period and of serial interval or generation time. From these, transmission times relative to symptom onset were calculated and the proportion of pre-symptomatic transmission was estimated.Results A total of 23 estimates of serial interval and five estimates of generation time from 17 publications were included. These came from nine different data source categories (presented here in descending order of the proportion of pre-symptomatic transmission): Hong Kong, Tianjin, pooled data from Hong Kong and Shenzhen, Singapore, Mainland China excluding Hubei, mixed sources, Shenzhen, northern Italy and Wuhan. Transmission time relative to symptom onset ranged from a mean of 2.05 days before symptom onset for Hong Kong to 1.72 days after symptom onset for Wuhan. Proportion of pre-symptomatic transmission ranged from 33.7% in Wuhan to 72.7% in Hong Kong. Based on individual estimates, transmission time relative to symptom onset ranged from mean of 2.95 days before symptom onset to 1.72 days after symptom onset and proportion of pre-symptomatic transmission ranged from 33.7% to 79.9%. Simple unweighted pooling of estimates based on serial intervals resulted in a mean time of transmission of 0.67 days before symptoms, and an estimated 56.1% of transmission occurring in the pre-symptomatic period.Conclusions Contact rates between symptomatic infectious and susceptible people are likely to influence the proportion of pre-symptomatic transmission. There is substantial potential for pre-symptomatic transmission of COVID-19 in a range of different contexts. Our work suggests that transmission of SARS-CoV-2 is most likely in the day before symptom onset whereas estimates suggesting most pre-symptomatic transmission highlighted a mean transmission times almost 3 days before symptom onset. These findings highlight the urgent need for extremely rapid and effective case detection, contact tracing and quarantine measures if strict social distancing measures are to be eased.Strengths and weaknesses of this studyWe contribute evidence about the extent and variation of pre-symptomatic transmission of COVID-19 across a range of contexts. This provides key information for development and targeting of control policies.This is a secondary analysis using simulations based on published data, some of which is in pre-print form and not yet peer-reviewed. There is overlap in the contact tracing data that informed some of our source publications. We partially addressed this by summarising data at source location level as well as at study level.A strength of our approach is that it builds a picture of pre-symptomatic transmission from a range of estimates in the literature, facilitates discussion for the drivers of variation between them, and highlights the consistent message that consideration of pre-symptomatic transmission is critical for COVID-19 control policy.What is already known about this topicCOVID-19 has spread rapidly, prompting calls for understanding about key transmission characteristics.Case-reports highlight the potential for people to transmit COVID-19 before they develop symptoms.Virological studies report high viral loads at the time of symptom onset and suggest the possibility for substantial viral shedding before symptom onset.Quantitative analyses of contact tracing data show that pre-symptomatic transmission of COVID-19 occurs in certain contexts.What this study addsWe estimate the proportion and timing of pre-symptomatic transmission from a range of different contexts.Despite the variation between estimates based on different studies, we highlight the consistent finding that a substantial amount of pre-symptomatic transmission can occur.We clarify the conceptual difference between asymptomatic and pre-symptomatic transmission which has not always been clear in the literature, and has relevance for control measures, disease transmission modelling and further research efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll investigators are full-time employees (or retired former employees) of University College Dublin, the Irish Department of Agriculture, Food and the Marine (DAFM), or the Irish Health information and Quality Authority (HIQA). No additional funding was obtained for this research.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in this manuscript are publicly available. ER -